A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Inclusion criteria

• Male participants: will be sterile (including vasectomy) or agree to use an effective method of birth control and will not donate sperm during the study and for 3 months following the last dose of the investigational product
• Female participants: women not of childbearing potential

Exclusion criteria

• Have a history of or current, significant ophthalmic disease, as determined by the investigator or ophthalmologist
• Have vitiligo or any other clinically significant disorder of skin pigmentation as determined by the investigator or dermatologist
• Have a history or presence of significant bleeding disorders
• Have a history of gastrointestinal ulcers with hemorrhage
• Have a personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations
• Self-reported history of increased bleeding from trauma
• Have a history of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within the last 3 months prior to screening
• History of major surgery within 3 months of screening
• Planned surgery within 14 days after the last day of dosing
• International Normalized Ratio (INR)/ Prothrombin Time (PT) or activated partial thromboplastin time above the normal reference range at screening
• Abnormal Protein S antigen and/or Protein C activity as determined by the investigator
• History of deep vein thrombosis and/or pulmonary embolism